DOI: https://doi.org/10.36347/sajb.2026.v14i04.006

Pages: 355-366

The design and synthesis of pyrimidoquinoline derivatives were systematically explored to address the urgent need for novel, potent anticancer agents with improved selectivity and reduced systemic toxicity. This research focused on the strategic integration of the pyrimidine and quinoline scaffolds, two pharmacologically significant heterocycles, to farm a fused tricyclic system capable of multi-target inhibition. Various synthetic methodologies, including multi-component reactions and microwave assisted cyclization, were employed to generate a diverse library of derivatives. These strategies were guided by Structure Activity Relationship (SAR) analyses, which highlighted the critical role of specific functional group substitutions particularly at the C-2 and C-4 positions in Modulating Electronic Properties (MEP) and Enhancing Molecular Minding (EMM) affinities within the ATP-binding pockets of protein kinases. The anticancer potential of the synthesized compounds was rigorously evaluated through in vitro cytotoxic analyses against a collection of samples of cancer cells, including breast (MCF-7), lung (A549), and colon (HCT-116) carcinomas. Several derivatives show significant antiproliferative activity, with IC50 values in the sub-micromolar range, outperforming standard reference drugs in specific instances. Mechanistic investigations, including flow cytometry and Molecular Docking Simulations (MDS), indicated that the most active compounds induced apoptosis and effectively inhibited angiogenesis-related signaling pathways. Future prospects for this scaffold were identified in the optimization of pharmacological profiles through the development of nano-formulations and targeted drug delivery systems. The study concluded that the pyrimidoquinoline molecule act as a reliable for the development of next-generation chemotherapeutics. The successful synthesis and biological validation of these derivatives provided a foundational roadmap for future clinical evaluation